Jade Biosciences, Inc.

Jade Biosciences, Inc. announced the appointment of Mark Eisner, M.D., M.P.H., to its Board of Directors, effective June 25, 2026. Dr. Eisner brings over 25 years of leadership in clinical development and immunology, having previously served as Executive Vice President and Chief Medical Officer at Vir Biotechnology, and Chief Medical Officer at Sonoma Biotherapeutics and FibroGen. He also held a senior leadership role at Genentech/Roche, overseeing multinational development programs. The company's CEO, Tom Frohlich, emphasized Dr. Eisner's valuable experience in advancing innovative therapies from early clinical development to global commercialization, which will support Jade's pipeline of antibody-based therapies for autoimmune diseases.

Jade Biosciences, Inc. held its 2026 Annual Meeting, where stockholders approved an amendment to the Articles of Incorporation to waive jury trials in certain circumstances, effective June 10, 2026. The Board also adopted Amended and Restated Bylaws, effective June 9, 2026, to align with Nevada Revised Statutes, including changes for virtual meetings and updated voting standards. Additionally, stockholders elected two Class II Directors and ratified PricewaterhouseCoopers LLP as the independent auditor for 2026.

Jade Biosciences, a clinical-stage biotechnology company, announced the closing of its previously announced public offering. The company sold 11,500,000 shares of common stock, including shares from the underwriters' full option exercise, at $15.00 per share. This offering generated gross proceeds of $172.5 million for Jade. The company plans to use the net proceeds, along with existing cash, to fund clinical trials, preclinical studies, manufacturing, research and development, capital expenditures, and general corporate purposes.

Jade Biosciences, Inc. announced the pricing of a public offering of 10,000,000 shares of its common stock at $15.00 per share, expecting to raise $150.0 million in gross proceeds. The company also granted underwriters a 30-day option to purchase up to an additional 1,500,000 shares. The net proceeds, combined with existing cash, will be used to fund clinical trials, preclinical studies, manufacturing, research and development, capital expenditures, working capital, and other general corporate purposes. The offering is anticipated to close on June 5, 2026.

Jade Biosciences, Inc. announced its intention to conduct an underwritten public offering of its common stock or pre-funded warrants. The company plans to use the net proceeds from this offering, along with existing cash, to fund clinical trials, preclinical studies, manufacturing, and additional research and development activities. Jefferies, TD Cowen, and UBS Investment Bank are serving as joint book-running managers for the proposed offering.

Jade Biosciences announced positive interim results from its Phase 1 trial of JADE101, a novel anti-APRIL monoclonal antibody for IgA nephropathy (IgAN). The trial demonstrated approximately 70% IgA reductions sustained at 12 weeks, with projections for similar reductions at steady-state with quarterly dosing. JADE101 showed a faster, deeper, and more durable IgA-lowering effect and superior potency compared to other agents, alongside a favorable safety profile. The company has advanced JADE101 into a Phase 2 trial and plans to initiate a Phase 3 registrational trial in the first half of 2027.

Jade Biosciences, Inc. announced it will host a conference call and webcast on Monday, June 1, 2026, at 8:00 a.m. ET. The purpose of the call is to discuss results from the ongoing Phase 1 healthy volunteer study of JADE101, its lead candidate for immunoglobulin A nephropathy (IgAN). The data are expected to define the dosing strategy and further characterize JADE101’s clinical profile as a potentially differentiated therapy.

Jade Biosciences announced the dosing of the first participant in a first-in-human (FIH) Phase 1 clinical trial for JADE201. JADE201 is an investigational, half-life extended, afucosylated monoclonal antibody targeting the B cell activating factor receptor (BAFF-R) designed to deplete B cells. The company expects interim FIH data in 2027, which will inform indication prioritization across multiple potential autoimmune indications.

Jade Biosciences announced the dosing of the first participant in its Phase 2 JUNIPER trial for JADE101, targeting immunoglobulin A nephropathy (IgAN). JADE101 is a clinical-stage therapy designed to block APRIL, a key driver of pathogenic IgA production in IgAN, a chronic autoimmune kidney disease affecting approximately 169,000 people in the U.S. Interim data from the JUNIPER trial, which will evaluate JADE101 in approximately 30 participants, are anticipated in 2027. Preclinical data suggest JADE101 has ultra-high binding affinity and a differentiated profile supporting infrequent subcutaneous dosing.

Jade Biosciences reported a net loss of $(40.4) million for the three months ended March 31, 2026, an increase from $(38.2) million in the prior year period. Operating expenses significantly increased, driven by higher research and development and general and administrative costs. Despite increased cash burn from operations, the company maintains a strong liquidity position with $311.3 million in cash and investments, which is expected to fund operations for at least the next twelve months.